The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
Abstract
Aims: Dapagliflozin, a selective sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitor, reduces hyperglycaemia in patients with type 2 diabetes ( T2DM ) by increasing urinary glucose excretion. Owing to its mechanism of action, dapagliflozin could potentially affect the renal tubular transportation of bone minerals. Therefore, markers of bone formation and resorption and bone mineral density ( BMD ) were evaluated in patients with T2DM after 50 weeks of dapagliflozin treatment. Methods: This international, multi‐centre, randomized, parallel‐group, double‐blind, placebo‐controlled study ( ClinicalTrials.gov NCT00855166 ) enrolled patients with T2DM (women 55–75 years and men 30–75 years; HbA1c 6.5–8.5%; BMI ≥ 25 kg/m 2 ; body weight ≤ 120 kg) whose T2DM was inadequately controlled on metformin. One hundred and eighty‐two patients were randomly assigned 1:1 to receive dapagliflozin 10 mg/day or placebo added to open‐label metformin for a 24‐week double‐blind treatment period followed by a 78‐week site‐ and patient‐blinded extension period. At week 50, serum markers of bone formation (procollagen type 1 N‐terminal propeptide; P1NP ) and resorption (C‐terminal cross‐linking telopeptides of type I collagen; CTX ), bone mineral density ( BMD ) as assessed by standardized Dual‐Energy X‐ray Absorptiometry ( DXA ) measurements and adverse events of fracture were evaluated as safety objectives. Results: One hundred and sixty‐five patients (90.7%) completed the first 50 weeks. Compared with placebo, no significant changes from baseline in P1NP , CTX or BMD were identified over 50 weeks of dapagliflozin treatment, with no significant treatment‐by‐gender interactions. No fractures were reported. Conclusions: Dapagliflozin had no effect on markers of bone formation and resorption or BMD after 50 weeks of treatment in both male and post‐menopausal female patients whose T2DM was inadequately controlled on metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Self-citationSodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Cited by
Mechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Metadata
- Authors
- Ljunggren, Ö., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-06-29
- Volume
- 14
- Issue
- 11
- Pages
- 990-999
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2080383778
- Cited by
- 215
- References
- 3
- FWCI
- 13.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01630.x
- The paper
- Ljunggren, Ö., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2012). Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01630.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.